GlassScriptPhysician profile
Richard A Knipe
NPI 1336120336
$15,730.30
in general payments reported to CMS, 2019-2025
71 companies · $92.56 in 2025
The $92.56 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $1,033 · 2021: $508 · 2022: $4,361 · 2023: $5,356 · 2024: $2,363 · 2025: $92.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,062 · Consulting Fee: $2,450 · Honoraria: $200 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.08 |
| Consulting Fee | $2,450.00 |
| Honoraria | $200.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,862.25 | 2019-2024 | Erleada, Rybrevant, Darzalex |
| Novartis Pharmaceuticals Corporation | $1,018.40 | 2019-2024 | Kisqali, Piqray |
| Aveo Pharmaceuticals, INC. | $951.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $904.26 | 2019-2024 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $781.12 | 2019-2024 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $680.66 | 2019-2024 | |
| Daiichi Sankyo INC. | $525.56 | 2020-2024 | Enhertu |
| Lilly USA, LLC | $429.61 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $401.83 | 2019-2024 | Trodelvy |
| Beigene USA, INC. | $387.80 | 2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $359.38 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Alexion Pharmaceuticals, INC. | $336.14 | 2022-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $333.55 | 2020-2024 | Ojjaara |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Seagen INC. | $319.63 | 2019-2023 | Adcetris, Padcev, Tukysa |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $318.59 | 2022-2024 | |
| Genzyme Corporation | $316.25 | 2019-2024 | |
| Blueprint Medicines Corporation | $306.73 | 2020-2024 | Ayvakit |
| Genentech USA, INC. | $304.97 | 2019-2024 | Phesgo, Perjeta, Lunsumio |
| Amgen INC. | $303.26 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Incyte Corporation | $278.69 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $273.98 | 2019-2024 | |
| Astellas Pharma US INC | $239.36 | 2019-2024 | Cresemba, Xospata |
| Celgene Corporation | $218.20 | 2022-2024 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $215.57 | 2022-2024 | Fruzaqla, Alunbrig, Ninlaro |
| Jazz Pharmaceuticals INC. | $201.10 | 2023 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Eisai INC. | $172.08 | 2020-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $171.91 | 2022-2023 | Imbruvica |
| Cti Biopharma Corp. | $165.80 | 2022-2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $164.45 | 2022-2024 | Libtayo |
| Novocure INC. | $142.08 | 2019 | |
| Tersera Therapeutics LLC | $130.94 | 2019-2021 | |
| Emd Serono, INC. | $130.36 | 2019-2023 | Tepmetko, Bavencio |
| Exelixis INC. | $116.83 | 2019-2024 | Cabometyx |
| Springworks Therapeutics, INC. | $116.17 | 2024-2025 | Ogsiveo |
| Kite Pharma, INC. | $115.38 | 2020-2023 | |
| Puma Biotechnology, INC. | $107.08 | 2019-2023 | |
| Comsort, INC | $100.00 | 2019 | |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Stemline Therapeutics INC. | $95.98 | 2023-2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $88.37 | 2019-2024 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $82.68 | 2023-2024 | Orgovyx |
| Taiho Oncology, INC. | $74.24 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.23 | 2022-2023 | |
| Array Biopharma INC | $68.32 | 2019-2022 | |
| Csl Behring | $63.64 | 2021-2025 | Idelvion, Afstyla |
| Karyopharm Therapeutics INC. | $55.97 | 2023-2024 | Xpovio |
| Myovant Sciences INC. | $55.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.33 | 2020-2022 | |
| Fennec Pharmaceuticals, INC. | $46.98 | 2024-2025 | Fyarro, Pedmark |
| Mirati Therapeutics, INC. | $43.28 | 2023-2024 | Krazati |
| Smith+Nephew, INC. | $39.15 | 2019-2020 | |
| Novo Nordisk INC | $37.04 | 2023-2024 | Novoseven, Rebinyn, Novoeight |
| Myriad Genetic Laboratories, INC. | $31.50 | 2023 | Myrisk |
| Lexicon Pharmaceuticals, INC. | $26.79 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.46 | 2019 | |
| Dova Pharmaceuticals | $26.26 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $23.64 | 2023 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $23.21 | 2019 | |
| Morphosys, US INC. | $20.10 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $20.08 | 2023 | Beleodaq |
| Aurobindo Pharma USA, INC. | $20.00 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.95 | 2024 | Cosela |
| Global Blood Therapeutics, INC. | $18.16 | 2021 | |
| Ge Healthcare | $17.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.22 | 2023 | Xarelto |
| Eusa Pharma (US) LLC | $15.41 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.26 | 2023 | Givlaari |
| Sysmex America, INC. | $12.00 | 2019 | |
| Veracyte, INC. | $0.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Knipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.